These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 11535703)

  • 1. Why most randomized phase II cervical cancer chemoprevention trials are uninformative: lessons for the future.
    Follen M; Meyskens FL; Atkinson EN; Schottenfeld D
    J Natl Cancer Inst; 2001 Sep; 93(17):1293-6. PubMed ID: 11535703
    [No Abstract]   [Full Text] [Related]  

  • 2. The 2001 ASCCP management guidelines for cervical cytology.
    Ferris DG
    Am Fam Physician; 2004 Nov; 70(10):1866, 1868. PubMed ID: 15571055
    [No Abstract]   [Full Text] [Related]  

  • 3. Why phase II trials in cervical chemoprevention are negative: what have we learned?
    Follen M; Vlastos AT; Meyskens FL; Atkinson EN; Schottenfeld D
    Cancer Causes Control; 2002 Nov; 13(9):855-73. PubMed ID: 12462551
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The predictive value of cytologic testing in women with the human immunodeficiency virus who have low-grade squamous cervical lesions: a substudy of a randomized, phase III chemoprevention trial.
    Robinson WR; Luck MB; Kendall MA; Darragh TM
    Am J Obstet Gynecol; 2003 Apr; 188(4):896-900. PubMed ID: 12712082
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of HPV DNA testing with cytology triage and/or repeat HPV DNA testing in primary cervical cancer screening.
    Naucler P; Ryd W; Törnberg S; Strand A; Wadell G; Elfgren K; Rådberg T; Strander B; Forslund O; Hansson BG; Hagmar B; Johansson B; Rylander E; Dillner J
    J Natl Cancer Inst; 2009 Jan; 101(2):88-99. PubMed ID: 19141778
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New tests for cervical cancer screening.
    Apgar BS
    Am Fam Physician; 2001 Sep; 64(5):729-30, 732. PubMed ID: 11563564
    [No Abstract]   [Full Text] [Related]  

  • 7. Biomarkers and their use in cervical cancer chemoprevention.
    Vlastos AT; Schottenfeld D; Follen M
    Crit Rev Oncol Hematol; 2003 Jun; 46(3):261-73. PubMed ID: 12791426
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prevention of cervix cancer.
    Rock CL; Michael CW; Reynolds RK; Ruffin MT
    Crit Rev Oncol Hematol; 2000 Mar; 33(3):169-85. PubMed ID: 10789491
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Does the ALTS trial apply to the community-based practitioner?
    Monk BJ; Brewster WR
    Am J Obstet Gynecol; 2003 Jun; 188(6):1381-2. PubMed ID: 12824966
    [No Abstract]   [Full Text] [Related]  

  • 10. Chemoprevention trials in the cervix: design, feasibility, and recruitment.
    Mitchell MF; Hittelman WN; Lotan R; Nishioka K; Tortolero-Luna G; Richards-Kortum R; Hong WK
    J Cell Biochem Suppl; 1995; 23():104-12. PubMed ID: 8747384
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Management of cervical cytologic abnormalities.
    Apgar BS; Brotzman G
    Am Fam Physician; 2004 Nov; 70(10):1905-16. PubMed ID: 15571057
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of self-collected vaginal, vulvar and urine samples with physician-collected cervical samples for human papillomavirus testing to detect high-grade squamous intraepithelial lesions.
    Sellors JW; Lorincz AT; Mahony JB; Mielzynska I; Lytwyn A; Roth P; Howard M; Chong S; Daya D; Chapman W; Chernesky M
    CMAJ; 2000 Sep; 163(5):513-8. PubMed ID: 11006761
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Papillomavirus screening: shall it be performed systematically?].
    Agius G; Beby-Defaux A
    Transfus Clin Biol; 2003 Apr; 10(2):86-9. PubMed ID: 12763151
    [No Abstract]   [Full Text] [Related]  

  • 14. The problems with different management options of women with minor squamous intraepithelial lesions in Pap tests.
    Varras M
    Clin Exp Obstet Gynecol; 2004; 31(4):249-50. PubMed ID: 15672956
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cervical chromosome 9 polysomy: validation and use as a surrogate endpoint biomarker in a 4-HPR chemoprevention trial.
    Kim HG; Yamal JM; Xu XC; Hu W; Boiko I; Linares A; Vlastos AT; Atkinson EN; Malpica A; Hittelman WN; Follen M
    Gynecol Oncol; 2005 Dec; 99(3 Suppl 1):S32-7. PubMed ID: 16154183
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prospective follow-up suggests similar risk of subsequent cervical intraepithelial neoplasia grade 2 or 3 among women with cervical intraepithelial neoplasia grade 1 or negative colposcopy and directed biopsy.
    Cox JT; Schiffman M; Solomon D;
    Am J Obstet Gynecol; 2003 Jun; 188(6):1406-12. PubMed ID: 12824970
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chemoprevention of cervical cancer.
    Sasieni P
    Best Pract Res Clin Obstet Gynaecol; 2006 Apr; 20(2):295-305. PubMed ID: 16386963
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Epidermal growth factor receptor expression in cervical intraepithelial neoplasia and its modulation during an alpha-difluoromethylornithine chemoprevention trial.
    Boiko IV; Mitchell MF; Hu W; Pandey DK; Mathevet P; Malpica A; Hittelman WN
    Clin Cancer Res; 1998 Jun; 4(6):1383-91. PubMed ID: 9626454
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Human papillomavirus testing and liquid-based cytology: results at recruitment from the new technologies for cervical cancer randomized controlled trial.
    Ronco G; Segnan N; Giorgi-Rossi P; Zappa M; Casadei GP; Carozzi F; Dalla Palma P; Del Mistro A; Folicaldi S; Gillio-Tos A; Nardo G; Naldoni C; Schincaglia P; Zorzi M; Confortini M; Cuzick J;
    J Natl Cancer Inst; 2006 Jun; 98(11):765-74. PubMed ID: 16757701
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 13-cis-retinoic acid for chemoprevention after colpoconization for cervical intraepithelial neoplasia.
    Kim SH; Park TK; Kwon JY
    Int J Gynaecol Obstet; 2003 May; 81(2):217-8. PubMed ID: 12706281
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.